Senseonics Holdings Inc (NYSEAMERICAN:SENS)’s stock price fell 6.4% during mid-day trading on Friday . The stock traded as low as $1.62 and last traded at $1.62, 1,831,074 shares were traded during mid-day trading. An increase of 12% from the average session volume of 1,628,995 shares. The stock had previously closed at $1.73.
Several research firms have recently commented on SENS. Zacks Investment Research downgraded Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 11th. Raymond James upped their target price on Intercontinental Exchange from $89.00 to $94.00 and gave the company an “outperform” rating in a research report on Friday, July 5th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $6.00.
Senseonics (NYSEAMERICAN:SENS) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.05). The firm had revenue of $3.42 million during the quarter, compared to the consensus estimate of $4.05 million.
Large investors have recently made changes to their positions in the stock. Amalgamated Bank bought a new position in Senseonics during the 4th quarter worth $28,000. First Allied Advisory Services Inc. acquired a new stake in Senseonics during the 4th quarter worth about $35,000. Creative Planning acquired a new stake in Senseonics during the 1st quarter worth about $34,000. Mogy Joel R Investment Counsel Inc. acquired a new stake in Senseonics during the 1st quarter worth about $37,000. Finally, Moors & Cabot Inc. acquired a new stake in Senseonics during the 1st quarter worth about $38,000. 30.66% of the stock is owned by institutional investors and hedge funds.
About Senseonics (NYSEAMERICAN:SENS)
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Recommended Story: What does a bar chart display?
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.